Regulators and HTA bodies for new designs in Europe - how to deal
with different priorities, especially for new design types?Chairs: Christoph Gerlinger (Bayer) and Andreas Brandt (BfARM)
- Talk 1 (15min): Dieter Haering & Marius Thomas, Novartis: Neos
pediatric trial of Kesimpta and Mayzent in multiple sclerosis.
- Talk 2 (20min): Theodor Framke (EMA & Med Hochschule Hannover):
Regulatory view on complex innovative designs
- Talk 3 (20min): Anders Viberg (Dental and Pharmaceutical Benefits
Agency, Sweden): HTA’s view on complex innovative designs
- Q&A and panel discussion (65min): Speakers + Anja Schiel + Kit Roes +
Katharina Hees + Franz Koenig
…Read more
Less…